



**Fig. S1. Collagen secretion in mutant cells.** Type I collagen secretion was evaluated by incubating the cells with  $^3\text{H}$ -Pro and extracting the collagen from both medium and cell layer fractions at the indicated time points. Samples were run on SDS-PAGE and the ratio between the densitometric value of collagen  $\alpha 1(\text{I})$  in the media and the total collagen  $\alpha 1(\text{I})$  (collagen present in medium and in cell layer) was evaluated and shown in the plot. Collagen secretion is delayed in the mutant cells tested compared to controls.



**Fig. S2. FACS analysis of mutant cells.** Representative plots of the fraction of apoptotic events in WT and OI patients' fibroblasts upon cells staining with annexin V (FITC) and propidium iodide (PI).



**Fig. S3. TUDCA does not ameliorate recessive OI fibroblasts homeostasis.** (A) Representative western blots (top) and quantitative analysis (bottom) of p-PERK and LC3II in absence (-) or in presence (+) of TUDCA in control (WT) cells and in cells with mutations in CRTAP, P3H1 and CypB. The levels of these proteins were compared in treated versus untreated cells. p-PERK/PERK and LC3II levels were unchanged.  $\beta$ -actin is used for normalization. (B) Quantitative analysis of the fraction of apoptotic events in the cell lines following FACS analysis upon cells staining with annexin V (FITC) and propidium iodide (PI). TUDCA did not reduce the percentage of apoptotic cells in mutant lines. \*  $p < 0.05$ .

**Table S1**

<b>Antibody</b>	<b>Company</b>	<b>Catalog Number</b>	<b>% Acrylamide running gel</b>
BiP	Cell signaling	31777	10
PDI	Cell signaling	3501	10
PERK	Cell signaling	5683	6
P PERK	Cell signaling	3179S	6
ATF6	Abcam	ab122897	10
ATF4	Novus biological	NB100-8525	10
LC3	Cell signaling kit	12741	15
Cleaved CASP3	Cell signaling kit	9915	15
CyPB	Proteintech	11607-1-AP	15
P3H1	Abnova	H00064175-b01p	10
CRTAP	Brendan Lee lab	Brendan Lee lab	10